Merck Opposes Delay In Wind-Down Of Fosamax MDL

Law360, New York (October 02, 2013, 6:58 PM ET) -- In a turnaround Friday, Merck & Co. Inc. urged a New York federal judge to stick to the planned wind-down of multidistrict litigation over jaw injuries allegedly caused by the bone drug Fosamax, after plaintiffs asked for a stay in the transfer of cases.

U.S. District Judge John Keenan decided in August to transfer 200 cases per month out of the multidistrict litigation and into their home courts beginning Nov. 1. Nearly 1,000 of the suits — which claim Fosamax users developed osteonecrosis of the jaw, also...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required